ARQT - Company ID 0001787306
The table below shows Arcutis Biotherapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $143.92M | $129.86M | $105.40M | $99.22M | $81.50M | $65.85M |
| Cost of revenue | $12.46M | $10.94M | $9.78M | $8.69M | $7.49M | $8.83M |
| Gross profit | - | - | - | - | - | - |
| R&D | $22.42M | $20.36M | $30.63M | $19.60M | $19.45M | $17.54M |
Arcutis Biotherapeutics, Inc. reported annual revenue of $376.07M for fiscal year 2025. That is up 91.3% from $196.54M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $99.60M |
| $82.14M |
| $74.08M |
| $62.40M |
| $69.17M |
| $64.00M |
| Operating income | $9.44M | $16.43M | -$9.09M | $8.53M | -$14.61M | -$24.53M |
| Income tax | $195.00K | $136.00K | $93.00K | $80.00K | $342.00K | $279.00K |
| Net income | $8.80M | $15.01M | -$11.29M | $7.41M | -$15.89M | -$25.06M |
| EPS (diluted) | $0.06 | $0.11 | -$0.09 | $0.06 | -$0.13 | -$0.20 |